The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1, 2012, Pages 47-57

  Asche, C V ^a   Bode, B ^b   Busk, A K ^c   Nair, S R ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b ATLANTA DIABETES ASSOCIATES   (United States)

^c NOVO NORDISK A S   (Denmark)

^d Knowledge Services   (India)

Author keywords

Clinical benefits; Cost; Insulin initiation; Insulin intensification; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH ECONOMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTERVENTION STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 83655161343     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01487.x     Document Type: Article

References (81)

1. Wirth A. Anti-diabetic drugs: weight reduction as a favourable side effect. Internist 2011; 52: 451-461.
2. Herman WH. The economics of diabetes prevention. Med Clin North Am 2011; 95: 373-384.
3. Eldor R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009; 6: 6-12.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Studies of Diabetes. Diabetes Care 2009; 32: 193-203.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
6. Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest 2006; 129: 644-650.
7. Peyrot M, Rubin RR, Lauritzen T et al. on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
8. Kazda C, Hülstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145-152.
9. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932.
10. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add- on therapy to oral glucose- lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
11. Al-Shaikh AR. Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes. Pak J Med Sci 2006; 1: 14-17.
12. Buse JB, Wolffenbuttel BH, Herman WH et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009; 32: 1007-1013.
13. McEwen LN, Bilik D, Johnson SL et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). Diabetes Care 2009; 32: 971-976.
14. Strojek K, Bebakar WMW, Khutsoane DT et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009; 25: 2887-2894.
15. Gross JL, Nakano M, Colon VG et al. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol Ther 2009; 11: S27-S34.
16. Milicevic Z, Hancu N, Car N, Ivanyi T, Schwarzenhofer M, Jermendy G. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. Clin Endocrinol Diabetes 2009; 117: 223-229.
17. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009; 31: 623-631.
18. Valensi P, Benroubi M, Borzi V et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 NovoMix 30 in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009; 63: 522-531.
19. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
20. Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Eng J Med 2009; 361: 1736-1747.
21. Yang W, Ji Q, Zhu D et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008; 31: 852-856.
22. Papa G, Fedele V, Chiavetta A et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta diabetologica 2008; 45: 53-59.
23. Ushakova O, Sokolovskaya V, Morozova A et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clin Ther 2007; 29: 2374-2384.
24. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007; 23: 3017-3023.
25. Karter AJ, Moffet HH, Liu J et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007; 13: 598-606.
26. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007, 78: 254-258.
27. Bebakar WMW, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 724-732.
28. Janka HU, Plewe G, Riddle MC, Kliebe FC, Schweitzer MA, Yki JH. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
29. Ray JA, Valentine WJ, Roze S et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost- effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metab 2007; 9: 103-113.
30. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006: 63: 2473-2482.
31. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
32. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006; 8: 39-48.
33. Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naÏve type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005; 21: 2063-2071.
34. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre FB. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22: 374-381.
35. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once- daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-313.
36. Alvarsson M, Sundkvist G, Lager I et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008; 10: 421-429.
37. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams HB, Raskin P. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009; 32: 1789-1795.
38. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009; 63: 425-432.
39. Davidson JA, Liebl A, Christiansen JS et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther 2009; 31: 1641-1651.
40. Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine Diabetes Technol Ther 2009; 11: S63-S73.
41. Davies MJ, Thaware PK, Tringham JR et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin Diabet Med 2007; 24: 714-719.
42. Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 527-532.
43. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
44. Herman WH, Ilag LL, Johnson SL et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes Diabetes Care 2005; 28: 1568-1573.
45. Hendra TJ, Taylor CD. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. J Diabetes Complications 2004; 3: 148-154.
46. Rosenstock J, Ahmann AJ, Colon G, Scism BJ, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed insulin lispro protamine suspension/lispro versus basal/bolus glargine/lispro therapy. Diabetes Care 2008; 31: 20-25.
47. Kärvestedt L, Andersson G, Efendic S, Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 2002; 251: 307-316.
48. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
49. Jang HC, Guler S, Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008; 62: 1013-1018.
50. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients JDDM 11. Diabetes Res Clin Pract 2008; 79: 171-176.
51. Jacober SJ, Scism BJL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naÏve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-455.
52. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
53. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of- concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162-167.
54. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-454.
55. Raskin P, Bode BW, Marks JB et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003; 26: 2598-2603.
56. Umpierrez GE, Smiley D, Zisman A et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181-2186.
57. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
58. Murase Y, Yagi K, Sugihara M et al. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. Intern Med 2004; 43: 779-786.
59. Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004; 36: 188-193.
60. Miyashita Y, Nishimura R, Nemoto M et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure, Cardiovasc Diabetol 2008; 7: 16.
61. Mathur SK, Bansal A, Khan ZY. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens. J Indian Med Assoc 2009; 107: 759-761.
62. Dashora U, Ashwell SG, Home PD. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab 2009; 11: 680-687.
63. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 1178-1185.
64. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 45-52.
65. Fajardo MC, Hernández HC, Rivas FM. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008; 25: 916-923.
66. Tamaki M, Shimizu T, Kanazawa A et al. Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract 2008; 81: e1-e3.
67. Ceriello A, Del PS, Bue VJ et al. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. J Diabetes Complications 2007; 21: 20-27.
68. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006; 73: 35-40.
69. Abrahamian H, Ludvik B, Schernthaner G et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs modern insulin regimens results from the Austrian Biaspart Study. Horm Metab Res 2005; 37: 684-689.
70. Sargin H, Sargin M, Altuntas Y et al. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. Diabetes Res Clin Pract 2003; 62: 79-86.
71. Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 2003; 5: 311-316.
72. Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
73. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
74. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007; 29: 1236-1253.
75. American Association of Clinical Endocrinologists. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement, 2 February 2005. Available from URL: Accessed 04 March 2011.
76. Liebl A. Myths, realities and practicalities in the initiation and intensification of insulin therapy in type 2 diabetes: a report. Available from URL: Accessed 01 April 2011.
77. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
78. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011; 33: 74-109.
79. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther 2010; 12: S101-S108.
80. Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009; 9: 1-9.
81. Umpierrez GE, Smiley D, Jacobs S et al. Randomized study of basal bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34: 256-261.